Annexon Inc (ANNX)

$4.72 -0.48 (-9.23%)
Market Cap 851.98M
Revenue (ttm) 0.00
Net Income (ttm) -206.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,627,000
Avg Vol 2,450,116
Day's Range N/A - N/A
Shares Out 163.84M
Stochastic %K 4%
Beta 1.18
Analysts Strong Sell
Price Target $13.55

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
Lightening_strikes
Lightening_strikes Jun. 11 at 3:53 AM
$ANNX significant director lead buying at 5.40 and this thing has tanked Unusual Why??
1 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 7:30 PM
$ANNX I think investors are tired of “good question” and we are “really excited” from Love. How many years of this bs?
1 · Reply
makingdoughfromoptions
makingdoughfromoptions Jun. 10 at 6:51 PM
$ANNX @ Chole1: You may be right on today's price action, but with a what 80% ish or better chance of GBS approval and a decent, minimally 50% chance of a decent GA P3 read you think he has done a shit job? Give me a break, all this stuff takes time and if you expect instant drug approvals you are plain wrong. Next year is their year, not this. Current SP is a steal.
1 · Reply
chole1
chole1 Jun. 10 at 6:20 PM
$ANNX invested for quite some time, with the CEO promising the same milestones since 18 months (US data, FDA filing, deal for GBS in EU/ROW, POC data for oral) but not delivering on it. The result is that investors are all exposed to the binary P3 update, which not all want to hold out for. Today's weakness probably a cross read to SNY C1 failure in CIDP
3 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 6:11 PM
$ANNX maybe fears of dilution? Dr love talking about non dilutive but never seems to execute
2 · Reply
Determinedstocks
Determinedstocks Jun. 10 at 5:52 PM
$ANNX Had to snap more shares
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 3:46 PM
$ANNX this trades like I’m missing something
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 3:18 PM
$ANNX we have a real winner here folks ?????
1 · Reply
NewBee13
NewBee13 Jun. 10 at 1:59 PM
$ANNX Lets see a trend towards $6
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jun. 10 at 12:14 AM
$ANNX cus that’s what all current standard of care treatment is based on despite the fact that none of them have proven vision preservation. Crappy diligence by the FDA in accepting the prior studies based on lesion size only, thinking that smaller lesion better vision…WRONG…we say to patients “ it’s not how it looks (to us) it’s how you see” If ANX007 confirms vision preservation in this Ph3 this will be worth 10’s of billions!
1 · Reply
Latest News on ANNX
Annexon Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 8:00 AM EDT - 1 day ago

Annexon Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Annexon Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:40 AM EDT - 7 days ago

Annexon Transcript: Jefferies Global Healthcare Conference 2026

Annexon to Participate in Upcoming June Investor Conferences

May 27, 2026, 8:00 AM EDT - 14 days ago

Annexon to Participate in Upcoming June Investor Conferences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026, 4:05 PM EDT - 23 days ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 4 weeks ago

Annexon Transcript: Bank of America Global Healthcare Conference 2026

Annexon initiated with a Neutral at Goldman Sachs

2026-05-12T09:15:39.000Z - 4 weeks ago

Annexon initiated with a Neutral at Goldman Sachs

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

May 11, 2026, 10:00 AM EDT - 4 weeks ago

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Annexon reports Q1 EPS (23c), consensus (30c)

2026-05-07T21:46:09.000Z - 4 weeks ago

Annexon reports Q1 EPS (23c), consensus (30c)

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 7, 2026, 4:01 PM EDT - 4 weeks ago

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Annexon Quarterly report: Q1 2026

Annexon Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Annexon Earnings release: Q1 2026

Annexon to Present at the Bank of America Securities Health Care Conference 2026

May 6, 2026, 8:00 AM EDT - 5 weeks ago

Annexon to Present at the Bank of America Securities Health Care Conference 2026

Annexon Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Annexon Proxy statement: Proxy filing

Annexon Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Annexon Proxy statement: Proxy filing

Annexon Slides: Corporate presentation

Apr 27, 2026, 7:00 AM EDT - 6 weeks ago

Annexon Slides: Corporate presentation

Annexon Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Annexon Proxy statement: Proxy filing

Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 11:45 AM EDT - 2 months ago

Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 2 months ago

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal

2026-03-31T17:10:51.000Z - 2 months ago

Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal

APLS BIIB OCGN

Annexon files automatic mixed securities shelf

2026-03-31T10:20:07.000Z - 2 months ago

Annexon files automatic mixed securities shelf

Annexon reports Q4 EPS (28c), consensus (32c)

2026-03-30T20:18:52.000Z - 2 months ago

Annexon reports Q4 EPS (28c), consensus (32c)

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 30, 2026, 4:01 PM EDT - 2 months ago

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Annexon Earnings release: Q4 2025

Annexon Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Annexon Annual report: Q4 2025

Annexon Transcript: KOL event

Mar 18, 2026, 2:00 PM EDT - 3 months ago

Annexon Transcript: KOL event

Annexon Slides: KOL event

Mar 18, 2026, 2:00 PM EDT - 3 months ago

Annexon Slides: KOL event

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Mar 16, 2026, 4:05 PM EDT - 3 months ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:50 AM EST - 3 months ago

Annexon Transcript: TD Cowen 46th Annual Health Care Conference

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 3 months ago

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Feb 17, 2026, 8:00 AM EST - 4 months ago

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Annexon Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 5 months ago

Annexon Transcript: 44th Annual J.P. Morgan Healthcare Conference

Annexon Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 5 months ago

Annexon Slides: 44th Annual J.P. Morgan Healthcare Conference

Annexon highlights its 2026 strategic priorities

2026-01-12T12:39:27.000Z - 5 months ago

Annexon highlights its 2026 strategic priorities

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Jan 12, 2026, 7:00 AM EST - 5 months ago

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Annexon submits MAA to EMA for tanruprubart

2026-01-08T13:05:13.000Z - 5 months ago

Annexon submits MAA to EMA for tanruprubart

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Jan 8, 2026, 8:00 AM EST - 5 months ago

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 5 months ago

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Annexon initiated with a Buy at Chardan

2025-12-23T09:35:20.000Z - 6 months ago

Annexon initiated with a Buy at Chardan

Annexon initiated with a Buy at Clear Street

2025-12-01T21:20:32.000Z - 6 months ago

Annexon initiated with a Buy at Clear Street

Annexon price target raised to $27 from $14 at Wells Fargo

2025-11-19T11:35:39.000Z - 7 months ago

Annexon price target raised to $27 from $14 at Wells Fargo

Annexon Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:30 AM EST - 7 months ago

Annexon Transcript: Jefferies London Healthcare Conference 2025

Annexon price target lowered to $8 from $9 at BofA

2025-11-17T14:30:07.000Z - 7 months ago

Annexon price target lowered to $8 from $9 at BofA

Annexon price target lowered to $8 from $9 at BofA

2025-11-16T15:55:10.000Z - 7 months ago

Annexon price target lowered to $8 from $9 at BofA

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Nov 14, 2025, 4:01 PM EST - 7 months ago

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Annexon 25.1M share Spot Secondary priced at $2.60

2025-11-13T04:25:17.000Z - 7 months ago

Annexon 25.1M share Spot Secondary priced at $2.60

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 10:55 PM EST - 7 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Annexon announces $75M common stock, warrants offering

2025-11-12T21:23:07.000Z - 7 months ago

Annexon announces $75M common stock, warrants offering

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 4:12 PM EST - 7 months ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Annexon reports Q3 EPS (37c), consensus (34c)

2025-11-10T21:40:18.000Z - 7 months ago

Annexon reports Q3 EPS (37c), consensus (34c)

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Nov 10, 2025, 4:05 PM EST - 7 months ago

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

Annexon Earnings release: Q3 2025

Annexon Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

Annexon Quarterly report: Q3 2025

Annexon participates in a conference call with JPMorgan

2025-09-15T14:40:07.000Z - 9 months ago

Annexon participates in a conference call with JPMorgan

Annexon Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Annexon Transcript: Cantor Global Healthcare Conference 2025

Annexon Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:00 PM EDT - 10 months ago

Annexon Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 10 months ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon reports Q2 EPS (34c), consensus (36c)

2025-08-14T20:36:16.000Z - 10 months ago

Annexon reports Q2 EPS (34c), consensus (36c)

Annexon reports Q2 EPS (34c), consensus (36c)

2025-08-14T20:15:45.000Z - 10 months ago

Annexon reports Q2 EPS (34c), consensus (36c)

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 14, 2025, 4:05 PM EDT - 10 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Annexon Earnings release: Q2 2025

Annexon Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Annexon Quarterly report: Q2 2025

Annexon Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Annexon Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Annexon Slides: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Annexon Slides: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon completes enrollment in Phase 3 ARCHER II trial

2025-07-24T11:15:36.000Z - 11 months ago

Annexon completes enrollment in Phase 3 ARCHER II trial

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 11 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon tells Wells Fargo doctor tweet not factural

2025-07-10T17:50:08.000Z - 11 months ago

Annexon tells Wells Fargo doctor tweet not factural

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Jun 18, 2025, 4:05 PM EDT - 1 year ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Annexon Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Annexon Transcript: Jefferies Global Healthcare Conference 2025

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 1 year ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025, 4:05 PM EDT - 1 year ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

Annexon Earnings release: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

Annexon Earnings release: Q1 2025

Annexon Quarterly report: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

Annexon Quarterly report: Q1 2025

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025, 5:00 PM EDT - 1 year ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025, 8:00 AM EDT - 1 year ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Annexon Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Annexon Proxy statement: Proxy Filing

Annexon Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Annexon Proxy statement: Proxy Filing

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 1 year ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Annexon Transcript: TD Cowen 45th Annual Healthcare Conference

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 3, 2025, 8:00 AM EST - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Annual report: Q4 2024

Mar 3, 2025, 12:00 AM EST - 1 year ago

Annexon Annual report: Q4 2024

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Feb 13, 2025, 8:30 AM EST - 1 year ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Annexon Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Annexon Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Annexon Slides: FY 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Annexon Slides: FY 2025

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon Transcript: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Transcript: Study Result

Annexon Press release: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Press release: Study Result

Annexon Slides: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Slides: Study Result

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 16, 2024, 7:30 AM EST - 1 year ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Annexon Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 5:30 AM EST - 1 year ago

Annexon Transcript: Jefferies London Healthcare Conference 2024

Annexon Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Annexon Quarterly report: Q3 2024

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Annexon Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:05 PM EDT - 1 year ago

Annexon Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Annexon Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 9:30 AM EDT - 1 year ago

Annexon Transcript: 2024 Wells Fargo Healthcare Conference

Annexon Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Annexon Quarterly report: Q2 2024

Annexon Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Annexon Earnings release: Q2 2024

Annexon Registration statement: Registration Filing

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Annexon Registration statement: Registration Filing

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jul 11, 2024, 6:09 PM EDT - 2 years ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 25, 2024, 5:00 PM EDT - 2 years ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 5, 2024, 11:04 PM EDT - 2 years ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 2 years ago

Annexon Announces Proposed Public Offering of Common Stock

Annexon Transcript: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Transcript: Study Update

Annexon Press release: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Press release: Study Update

Annexon Slides: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Slides: Study Update

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 4, 2024, 7:11 AM EDT - 2 years ago

Annexon's neurological disorder drug meets main goal of late-stage study

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Jun 3, 2024, 4:30 PM EDT - 2 years ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Annexon Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 11:40 AM EDT - 2 years ago

Annexon Transcript: BofA Securities 2024 Health Care Conference

Annexon Quarterly report: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Annexon Quarterly report: Q1 2024

Annexon Earnings release: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Annexon Earnings release: Q1 2024

Annexon Slides: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Annexon Slides: Q1 2024

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 13, 2024, 8:00 AM EDT - 2 years ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 7, 2024, 12:30 PM EDT - 2 years ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 2 years ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Annexon Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Annexon Proxy statement: Proxy Filing

Annexon Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Annexon Proxy statement: Proxy Filing

Annexon Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 11:00 AM EDT - 2 years ago

Annexon Transcript: 23rd Annual Needham Virtual Healthcare Conference

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Mar 26, 2024, 4:05 PM EDT - 2 years ago

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Lightening_strikes
Lightening_strikes Jun. 11 at 3:53 AM
$ANNX significant director lead buying at 5.40 and this thing has tanked Unusual Why??
1 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 7:30 PM
$ANNX I think investors are tired of “good question” and we are “really excited” from Love. How many years of this bs?
1 · Reply
makingdoughfromoptions
makingdoughfromoptions Jun. 10 at 6:51 PM
$ANNX @ Chole1: You may be right on today's price action, but with a what 80% ish or better chance of GBS approval and a decent, minimally 50% chance of a decent GA P3 read you think he has done a shit job? Give me a break, all this stuff takes time and if you expect instant drug approvals you are plain wrong. Next year is their year, not this. Current SP is a steal.
1 · Reply
chole1
chole1 Jun. 10 at 6:20 PM
$ANNX invested for quite some time, with the CEO promising the same milestones since 18 months (US data, FDA filing, deal for GBS in EU/ROW, POC data for oral) but not delivering on it. The result is that investors are all exposed to the binary P3 update, which not all want to hold out for. Today's weakness probably a cross read to SNY C1 failure in CIDP
3 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 6:11 PM
$ANNX maybe fears of dilution? Dr love talking about non dilutive but never seems to execute
2 · Reply
Determinedstocks
Determinedstocks Jun. 10 at 5:52 PM
$ANNX Had to snap more shares
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 3:46 PM
$ANNX this trades like I’m missing something
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 10 at 3:18 PM
$ANNX we have a real winner here folks ?????
1 · Reply
NewBee13
NewBee13 Jun. 10 at 1:59 PM
$ANNX Lets see a trend towards $6
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jun. 10 at 12:14 AM
$ANNX cus that’s what all current standard of care treatment is based on despite the fact that none of them have proven vision preservation. Crappy diligence by the FDA in accepting the prior studies based on lesion size only, thinking that smaller lesion better vision…WRONG…we say to patients “ it’s not how it looks (to us) it’s how you see” If ANX007 confirms vision preservation in this Ph3 this will be worth 10’s of billions!
1 · Reply
Lightening_strikes
Lightening_strikes Jun. 9 at 11:45 PM
$ANNX why Does the dumb gs analyst continue to push dr love on lesions?
0 · Reply
Thomas105
Thomas105 Jun. 9 at 3:39 PM
$ANNX no chance for green today to heavy bids under 5$ stay bullish
1 · Reply
Lightening_strikes
Lightening_strikes Jun. 9 at 2:23 PM
$ANNX I did hear something new Forward study data release end of summer
0 · Reply
MarketBeat
MarketBeat Jun. 9 at 1:08 PM
https://marketbeat.com/a/8703275/ $ANNX Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 9 at 12:38 PM
$ANNX anything new today at GS?
0 · Reply
Thomas105
Thomas105 Jun. 9 at 8:03 AM
$ANNX Today before markets open
1 · Reply
NewBee13
NewBee13 Jun. 8 at 4:43 PM
$ANNX This is my fault. I added at 5.30 so inevitably it broke contain
0 · Reply
Montu11
Montu11 Jun. 8 at 4:11 PM
$ANNX 🥱🫩😴
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 5 at 8:07 PM
$ANNX needs some news
2 · Reply
NewBee13
NewBee13 Jun. 5 at 2:47 PM
$ANNX Market seems to be crap in general. See if theres a later day rally
1 · Reply
NewBee13
NewBee13 Jun. 5 at 12:03 PM
$ANNX Jumped back in at 5.42 later yesterday. I think it'll stetch its legs again today. But if it drops I'll happily load up
0 · Reply
Lightening_strikes
Lightening_strikes Jun. 4 at 4:24 PM
$ANNX can’t hold any rally Lets go dr love get that licensing deal All else is just more talk
0 · Reply